Radiomic Phenotypes for Improving Early Prediction of Survival in Stage III Non-Small Cell Lung Cancer Adenocarcinoma after Chemoradiation.
ComBat
computed tomography
non-small cell lung cancer
overall survival
radiomics
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
29 Jan 2022
29 Jan 2022
Historique:
received:
14
11
2021
revised:
23
01
2022
accepted:
28
01
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
16
2
2022
Statut:
epublish
Résumé
We evaluate radiomic phenotypes derived from CT scans as early predictors of overall survival (OS) after chemoradiation in stage III primary lung adenocarcinoma. We retrospectively analyzed 110 thoracic CT scans acquired between April 2012-October 2018. Patients received a median radiation dose of 66.6 Gy at 1.8 Gy/fraction delivered with proton (55.5%) and photon (44.5%) beam treatment, as well as concurrent chemotherapy (89%) with carboplatin-based (55.5%) and cisplatin-based (36.4%) doublets. A total of 56 death events were recorded. Using manual tumor segmentations, 107 radiomic features were extracted. Feature harmonization using ComBat was performed to mitigate image heterogeneity due to the presence or lack of intravenous contrast material and variability in CT scanner vendors. A binary radiomic phenotype to predict OS was derived through the unsupervised hierarchical clustering of the first principal components explaining 85% of the variance of the radiomic features. C-scores and likelihood ratio tests (LRT) were used to compare the performance of a baseline Cox model based on ECOG status and age, with a model integrating the radiomic phenotype with such clinical predictors. The model integrating the radiomic phenotype (C-score = 0.69, 95% CI = (0.62, 0.77)) significantly improved (p<0.005) upon the baseline model (C-score = 0.65, CI = (0.57, 0.73)). Our results suggest that harmonized radiomic phenotypes can significantly improve OS prediction in stage III NSCLC after chemoradiation.
Identifiants
pubmed: 35158971
pii: cancers14030700
doi: 10.3390/cancers14030700
pmc: PMC8833400
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NIEHS NIH HHS
ID : P30 ES013508
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA264835
Pays : United States
Organisme : NIH HHS
ID : S10 OD023495
Pays : United States
Organisme : NIBIB NIH HHS
ID : T32 EB009384
Pays : United States
Références
Insights Imaging. 2020 Aug 12;11(1):91
pubmed: 32785796
J Clin Oncol. 2016 Mar 20;34(9):953-62
pubmed: 26811519
Nat Methods. 2020 Mar;17(3):261-272
pubmed: 32015543
Adv Exp Med Biol. 2016;893:1-19
pubmed: 26667336
Radiat Oncol. 2020 Feb 18;15(1):43
pubmed: 32070383
Nat Commun. 2014 Jun 03;5:4006
pubmed: 24892406
Lancet Oncol. 2019 Dec;20(12):1670-1680
pubmed: 31601496
Int J Radiat Oncol Biol Phys. 2017 Jan 1;97(1):128-137
pubmed: 27979443
Sci Rep. 2020 Aug 13;10(1):13773
pubmed: 32792640
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
Oncol Lett. 2012 Jan;3(1):16-18
pubmed: 22740848
Biostatistics. 2007 Jan;8(1):118-27
pubmed: 16632515
Nat Rev Clin Oncol. 2013 Jan;10(1):27-40
pubmed: 23165123
Ann Nucl Med. 2021 Jul;35(7):843-852
pubmed: 33948903
Med Phys. 2021 Jul;48(7):4099-4109
pubmed: 34008178
Mol Imaging Biol. 2021 Oct;23(5):756-765
pubmed: 33763816
Cancer. 2017 Dec 15;123 Suppl 24:5079-5099
pubmed: 29205305
Ann Oncol. 2017 Apr 1;28(4):777-783
pubmed: 28137739
Pract Radiat Oncol. 2015 May-Jun;5(3):141-148
pubmed: 25957184
Radiother Oncol. 2019 Jul;136:78-85
pubmed: 31015133
Br J Surg. 2015 Feb;102(3):148-58
pubmed: 25627261
Ann Oncol. 2020 Jun;31(6):798-806
pubmed: 32209338
Eur J Nucl Med Mol Imaging. 2019 Apr;46(4):864-877
pubmed: 30535746
Med Phys. 2020 Sep;47(9):4125-4136
pubmed: 32488865
Sci Rep. 2020 Sep 23;10(1):15496
pubmed: 32968131
Clin Radiol. 2019 Jun;74(6):467-473
pubmed: 30898382
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
J Stat Softw. 2018 Aug;86:
pubmed: 30288153
J Clin Oncol. 2008 Dec 10;26(35):5755-60
pubmed: 19001323
Med Phys. 2021 Jul;48(7):3691-3701
pubmed: 33894058
J Clin Oncol. 2005 Sep 1;23(25):5883-91
pubmed: 16087941
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
Ann Thorac Surg. 2020 Jun;109(6):1741-1749
pubmed: 32087134
Oncotarget. 2015 Nov 24;6(37):39676-91
pubmed: 26485755
Cancer Res. 2017 Nov 1;77(21):e104-e107
pubmed: 29092951
J Natl Cancer Inst. 2018 Aug 1;110(8):831-842
pubmed: 29518203
J Transl Med. 2019 Mar 27;17(1):99
pubmed: 30917841
Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):455-466
pubmed: 30173391
Sci Rep. 2017 May 2;7(1):1339
pubmed: 28465554
J Nucl Med. 2020 Jun;61(6):814-820
pubmed: 31732678
Oncologist. 2018 Jul;23(7):806-813
pubmed: 29622699
J Thorac Oncol. 2011 Feb;6(2):244-85
pubmed: 21252716
J Thorac Oncol. 2021 May;16(5):860-867
pubmed: 33476803
Clin Cancer Res. 2020 May 1;26(9):2151-2162
pubmed: 32198149
J Clin Oncol. 2003 May 15;21(10):2004-10
pubmed: 12743155
Pract Radiat Oncol. 2015 May-Jun;5(3):149-155
pubmed: 25957185
J Clin Oncol. 1995 Aug;13(8):1880-92
pubmed: 7636530
Lancet Oncol. 2015 Feb;16(2):187-99
pubmed: 25601342
J Med Imaging (Bellingham). 2020 Jan;7(1):012707
pubmed: 32206682
J Clin Oncol. 2017 Jan;35(1):56-62
pubmed: 28034064
Ann Thorac Surg. 2011 Jun;91(6):1668-73
pubmed: 21619963